KAEGAN CULLISON: Open Payments
NPI 1912744004 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$857 in 26 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $380 · 2025 $857
Food & beverage: $857
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 11 | $465 |
| Intercept Pharmaceuticals, Inc. | 5 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $52 |
| Veloxis Pharmaceuticals, Inc. | 2 | $50 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Eton Pharmaceuticals, Inc. | 1 | $24 |
| Gilead Sciences, Inc. | 1 | $18 |
Products named: REZDIFFRA, OCALIVA, LIVTENCITY, XIFAXAN, ENVARSUS, FANAPT, GALZIN.
Industry payments across OK — which companies pay providers there.
